Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Why AZ Respiratory Head Believes Third-Placed Benralizumab Can Conquer Market

Executive Summary

AstraZeneca hopes its investigative biologic benralizumab has strongly differentiated itself from rival therapies Nucala and Cinqair with the detailed publication of Phase III data showing it significantly cut exacerbations and improved lung function and symptoms in patients with severe eosinophilic asthma, as well as offering a favorable dosing schedule.

Advertisement

Related Content

Keeping Track: A Blizzard Of Submissions And A Small Flurry Of Approvals
GSK's Nucala Shows Promise In A Rare Systemic Vasculitis
Chiesi Takes Aim At Next-Generation Eosinophilic Asthma Therapy
Teva Under Pressure As NICE Calls For More Reslizumab Analyses
AstraZeneca Ends AZD9412 IFN-β Asthma Trial For Redesign, Relaunch
AstraZeneca Looks To Insmed To Advance AZD7986 In Bronchiectasis
AstraZeneca Hopes To Differentiate Benralizumab On Efficacy, Dosing Convenience

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097250

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel